Smither John W insider trades
Smither John W has filed 24 Form 4s with the SEC that we hold, for GENELUX Corp (GNLX) (Director), EFTR (Director), AMTI (Director) and NewAmsterdam Pharma Co N.V. (NAMS) (Director), among 6 companies in all. Across all of them we count 1 purchase worth $0 and 3 sales worth $94.1K reported on Form 4. In the last 12 months: 0 purchases ($0) and 2 sales ($75.4K). The largest single trade was a sale of 1,600 shares of NewAmsterdam Pharma Co N.V. worth $40.5K, dated 2026-09-04. Of 1 sale filed since we began reading the 10b5-1 checkbox, 0 (0%) were marked as made under a 10b5-1 trading plan. The first filing on our record is dated 2021-08-27 and the latest 2026-09-09.
GENELUX Corp (GNLX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-09-13 | S, sale reported on Form 4 | 900 | $18.7K | 2023-09-14 |
| 2024-05-29 | P, purchase reported on Form 4 | 6,250 | - | 2024-06-07 |
| 2026-07-01 | S, sale reported on Form 4 | 12,000 | $34.9K | 2026-07-02 |
EFTR
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
AMTI
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
NewAmsterdam Pharma Co N.V. (NAMS)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-09-04 | S, sale reported on Form 4 | 1,600 | $40.5K | 2026-09-09 |
Arcutis Biotherapeutics, Inc. (ARQT)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
MBX Biosciences, Inc. (MBX)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1559583) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms